(Q39012997)

8 September 2017

title

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer (English)

1 reference

8 September 2017

1 reference

T Tomar

2

0 references

author name string

N G Alkema

1

1 reference

8 September 2017

A G J van der Zee

3

1 reference

8 September 2017

M Everts

4

1 reference

8 September 2017

G J Meersma

5

1 reference

8 September 2017

H Hollema

6

1 reference

8 September 2017

S de Jong

7

1 reference

8 September 2017

M A T M van Vugt

8

1 reference

8 September 2017

G B A Wisman

9

1 reference

8 September 2017

language of work or name

English

0 references

publication date

20 March 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

133

1 reference

8 September 2017

issue

3

1 reference

8 September 2017

page(s)

591-598

1 reference

8 September 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Induction of DNA replication-mediated double strand breaks by psoralen DNA interstrand cross-links

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Chk1 and Chk2 kinases in checkpoint control and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Cell-cycle checkpoints and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Targeting the double-strand DNA break repair pathway as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Platinum resistance: the role of DNA repair pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

DNA damage induces two distinct modes of cell death in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

The role of ATM and 53BP1 as predictive markers in cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Concomitant inactivation of p53 and Chk2 in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

A mammalian functional-genetic approach to characterizing cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.557

10.1016/J.YGYNO.2014.03.557

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference